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Background: The metastasis-promoting protein S100A4 induces expression of ephrin-A1 and osteopontin in
osteosarcoma cell lines. The aim of this study was to investigate S100A4-mediated stimulation of ephrin-A1 and
osteopontin in non-small cell lung cancer (NSCLC) cell lines, and to characterize the expression of these biomarkers
in primary tumor tissue from NSCLC patients.
Methods: Four NSCLC cell lines were treated with extracellular S100A4, and ephrin-A1 and osteopontin expression
was analyzed by real time RT-PCR and Western blotting. Immunohistochemical staining for S100A4, ephrin-A1 and
osteopontin was performed on tissue microarrays containing primary tumor samples from a cohort of 217
prospectively recruited NSCLC patients, and associations with clinicopathological parameters were investigated.
Results: S100A4 induced ephrin-A1 mRNA and protein expression in adenocarcinoma, but not in squamous
carcinoma cell lines, whereas the level of osteopontin was unaffected by S100A4 treatment. In primary tumors,
moderate or strong immunoreactivity was observed in 57% of cases for cytoplasmic S100A4, 46% for nuclear
S100A4, 86% for ephrin-A1 and 77% for osteopontin. Interestingly, S100A4 expression was associated with
ephrin-A1 also in vivo, but there was no association between S100A4 and osteopontin. Expression levels of
S100A4 and ephrin-A1 were significantly higher in adenocarcinomas compared to other histological subtypes, and
S100A4-positive tumors were smaller and more differentiated than tumors without expression.
Conclusions: Our findings suggest that S100A4, ephrin-A1 and osteopontin are involved in the biology of NSCLC,
and further investigation of their potential use as biomarkers in NSCLC is warranted.
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Lung cancer is one of the most frequently occurring malig-
nancies, and the leading cause of cancer-related death in
men and the second leading cause in women [1]. Non-
small cell lung cancer (NSCLC) accounts for approximately
85% of all lung cancer cases, with adenocarcinoma, squa-
mous cell carcinoma and large cell carcinoma as the main
histological subtypes. Surgical resection or radiotherapy
have curative potential, and in Norway the 5-year survival
among patients with early stage disease who undergo* Correspondence: kjetil.boye@rr-research.no
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reproduction in any medium, provided the orcomplete surgical resection is approximately 65% [2]. Even
for stage I patients there is a significant risk of relapse, and
NSCLC carries one of the most dismal outcomes for stage I
disease among all tumor types [3]. Clearly, there is an ur-
gent need for more effective treatment as well as improved
classification algorithms to identify patients at increased risk
of relapse.
NSCLC patients who undergo curatively intended sur-
gery are stratified according to TNM (tumor-node-me-
tastasis) staging, and based on this patients are selected
for adjuvant therapy. However, tumors within the same
disease stage are biologically heterogeneous and behave
differently, and identification of biomarkers could enable
further subclassification of patients and thereby a more
accurate prediction of prognosis. Furthermore, the
increased use of targeted therapies in NSCLC requires. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tumor cells to facilitate therapeutic decisions.
One potentially interesting molecular marker is S100A4,
a member of the S100 family of calcium binding proteins.
S100A4 is localized in the cytoplasm, nucleus and extracel-
lular space and has multiple biological functions including
regulation of angiogenesis and stimulation of motility and
invasion. S100A4 promotes metastasis in several experi-
mental animal models and is associated with patient out-
come in a variety of cancer types [4]. In lung cancer,
experimental models have shown that there is an associ-
ation between S100A4 expression and motile and invasive
abilities, and that suppression of S100A4 results in reduced
metastatic potential [5,6].
Several studies have investigated S100A4 protein expres-
sion in NSCLC, with the percentage of positive cases ran-
ging from 20-84% [7-11]. In general, S100A4 is not
expressed in normal lung epithelium [7], whereas a variety
of cells in the tumor microenvironment are S100A4-posi-
tive, including lymphocytes, fibroblasts and smooth muscle
cells [9,10]. In some examinations, S100A4 expression has
been shown to be associated with pT stage and poor patient
outcome [9], while other studies have failed to demonstrate
a prognostic role for S100A4 in NSCLC [7,8].
Ephrin-A1 (Eph receptor interacting protein-A1) is a
cell surface protein which can act as a ligand for several
of the Eph receptor tyrosine kinases, such as EphA2,
EphA3 and EphA4 [12]. Ephrin-A1 is involved in mul-
tiple biological processes, including tumor angiogenesis
[13,14], cell motility [15] and metastasis [16,17]. To our
knowledge, the role of ephrin-A1 in lung cancer has not
been investigated, and based on its pro-metastatic func-
tions in other types of cancer, characterization of the ex-
pression in NSCLC would be of substantial interest.
Osteopontin, a member of the small integrin-binding
ligand N-linked glycoprotein (SIBLING) family, is a
secreted chemokine-like multifunctional protein. Bio-
logical processes regulated by osteopontin include adhe-
sion, migration, invasion, proteolysis, enhanced cell
survival and angiogenesis [18,19], and several studies
have shown an association between high osteopontin ex-
pression and poor patient outcome in NSCLC [20-22].
Our group has previously shown that extracellular
S100A4 induces the expression of ephrin-A1 and osteo-
pontin in osteosarcoma cell lines [18,23]. Based on the
reported biological effects of ephrin-A1 and osteopontin,
S100A4-induced expression of these molecules may be
one of several mechanisms by which S100A4 promotes
tumor progression. The aim of the present study was to
investigate whether S100A4 induces expression of ephrin-
A1 and osteopontin in NSCLC, and to characterize the
expression of these molecular markers in primary tumor
tissue from prospectively recruited patients undergoing
curative surgery for NSCLC. Furthermore, associationsbetween expression of these proteins and clinical and
histopathological parameters were investigated.
Methods
Cell culture and treatment
The human lung adenocarcinoma cell line EKVX was
established at Department of Tumor Biology, The Nor-
wegian Radium Hospital, Oslo University Hospital. The
adenocarcinoma cell line A549 and the squamous cell
carcinoma cell lines HTB-182 (NCI-H520) and SW900
(HTB-59), were purchased from the American Type
Culture Collection (Rockville, MD, USA). Recombinant
human S100A4 protein was produced as described pre-
viously [18]. Cells were cultivated in RPMI 1640 (Lonza,
Verviers, Belgium), supplemented with 8.5% fetal bovine
serum (PAA Laboratories, Pasching, Austria), 20 mM
Hepes buffer (Lonza) and 2 mM GlutaMAX (Gibco,
Invitrogen, Oslo, Norway). All cell cultures were rou-
tinely tested for Mycoplasma infection. The identity of
the cell lines were determined by STR profiling using
Powerplex 16 (Promega, Madison, WI, USA). For cell
culture experiments, subconfluent cell cultures were
detached with Versene EDTA (Lonza), and 1 × 106 cells
were seeded in T25 flasks and grown overnight. The fol-
lowing day, the culture medium was replaced with
medium with or without recombinant human S100A4
protein (2 μg/ml or 10 μg/ml) and further incubated for
6 or 24 hours. Cells were harvested by Tri-reagent
(Ambion, Applied Biosystems Europe, Oslo, Norway) for
RNA isolation, and by scraping for preparation of cell
lysates.
Real time RT-PCR
One microgram total RNA was reverse transcribed using
the iScript RT kit (Bio-Rad, Hercules, CA, USA). Gene
expression levels were examined by quantitative real-
time reverse transcription PCR (qPCR) as described in
Boye et al. [23] for ephrin-A1 and Berge et al. [18] for
osteopontin. The PCR threshold cycle number (Ct) was
used to calculate the relative expression of each gene
normalized to the expression of an endogenous control
gene as follows: 2−ΔCt, where ΔCt =Ctgene – Ctcontrol gene.
Western blot analysis
Western blotting was performed as described previously
[18]. Antibody against ephrin-A1 was obtained from
Santa Cruz Biotechnology (sc-911, Santa Cruz Biotech-
nology, Santa Cruz, CA, USA).
Patient cohort
Primary tumor samples were prospectively collected from
244 patients with assumed or verified NSCLC who were
considered operable and underwent curatively intended
surgical resection at Rikshospitalet, Oslo University
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2010. Following surgery, resected tissue was processed for
routine histopathological examination. The study was
approved by the Regional Ethics Committee (S-06402b),
and all patients were informed and signed a written con-
sent. Twenty-seven patients were excluded from the study
for the following reasons: histology other than NSCLC
(carcinoid (12), small cell lung cancer (4), lung metastases
from other primary cancer (7)) and withdrawal of consent
(4). The study population thus included 217 patients with
histologically verified primary NSCLC. Histological exam-
ination of all tissue specimens was performed by experi-
enced pathologists, and the histopathological parameters
were retrieved from the pathology reports. The tumors
were staged according to the International Association for
the Study of Lung Cancer (IASLC), TNM 7. The histo-
logical subtypes were classified according to WHO cri-
teria, with adenocarcinoma, squamous cell carcinoma and
large cell carcinoma as the three main types. Bronchioal-
veolar carcinomas were included in the adenocarcinoma
group, constituting 4.5% of these tumors. Seven patients
received neoadjuvant chemotherapy and/or radiation ther-
apy due to the following reasons: pancoast tumor, N2 dis-
ease and for downstaging of a primarily inoperable tumor.
The patients´ tobacco use was registered and divided into
three groups; current smoker, former smoker or never
smoker. Never smoker was defined as never having smoked
on a regular basis, and former smoker was defined as hav-
ing quit smoking at least one year before inclusion in the
study.
Tissue microarray (TMA) construction
TMA sections were constructed using a tissue arrayer in-
strument (Beecher Instruments, Silver Springs, MD, USA).
Formalin-fixed tumor tissue from 206 patients was avail-
able for TMA construction. The most representative
tumor areas in each donor block were selected by an
experienced pathologist and marked on hematoxylin-eosin
stained sections. From corresponding blocks, one mm core
biopsies were obtained from at least two different tumor-
rich areas, and two additional cores were selected from ad-
jacent normal lung tissue. The cores were inserted directly
into the recipient paraffin block in a grid arrangement, and
one slide from each prepared TMA block was stained with
hematoxylin-eosin for tumor tissue confirmation.
Immunohistochemistry
The TMA sections were immunostained for S100A4 and
osteopontin using the EnVisionTM FLEX+detection sys-
tem from Dako (Dako, Glostrup, Denmark). Dako PT
link was used for deparaffinization and heat-induced epi-
tope retrieval. Sections were preheated in Dako EnVision
FLEX+Target Retrieval Solution, High pH and rinsed in
Dako wash buffer according to the manufacturer´sinstructions. Thereafter, endogenous peroxidase activity
was blocked for 5 minutes using 0.03% H2O2, sections
were washed twice in Dako wash buffer and incubated
for 30 minutes with primary antibody at room
temperature. After an additional washing step, slides were
incubated with secondary antibody (HRP-labelled polymer
conjugated to anti-mouse or anti-rabbit immunoglobu-
lins) for 30 minutes at room temperature. After new
washing, sections were incubated for 10 minutes in DAB
(diaminobenzidine). Finally the sections were rinsed twice
in water before counterstaining with hematoxylin and
mounting in Diatex. The following primary antibodies
were used: mouse monoclonal anti-S100A4 (20.1) [24]
diluted 1:300 and rabbit polyclonal anti-osteopontin
diluted 1:300 (Rb-9097, Thermo Fisher Scientific, Fre-
mont, CA, USA). Ephrin-A1 immunostaining was done
using the EnVision+ system from Dako (Dako) as follows:
TMA slides were deparaffinized with xylene, rehydrated
through graded ethanol solutions and rinsed in distilled
water. For antigen retrieval, tissue sections were preheated
in a microwave oven at 100 ° C for 15 minutes in Tris/
EDTA solution, left in the buffer for 10 minutes after boil-
ing, rinsed in distilled water and in Dako wash buffer. The
rest of the procedure was performed as described for
S100A4 and osteopontin. The primary antibody used was
rabbit polyclonal anti-ephrin-A1 diluted 1:300 (sc-911,
Santa Cruz Biotechnology). Sections from colorectal
tumor tissue, ovarian tissue and cervical portio biopsy tis-
sue known to express high amounts of S100A4, osteopon-
tin and ephrin-A1, respectively, were used as positive
controls.
Evaluation of immunohistochemistry
All immunostained sections were evaluated by two
investigators (A.K.R and K.B for S100A4, and A.K.R and
M.L-I for ephrin-A1 and osteopontin), and discrepancies
were resolved by consensus. Immunohistochemical ex-
pression was evaluated without knowledge on the corre-
sponding clinicopathological parameters. In nine cases
staining was not evaluable due to lack of representative
tumor material. S100A4 immunoreactivity was apparent
as both cytoplasmic and nuclear staining, and these were
recorded as individual variables (S100A4c and S100A4n,
respectively). The samples were scored using a 0–3 scale
according to staining intensity, with 0 denoting negative
(no staining), 1 denoting weak staining, 2 intermediate
staining and 3 strong staining. For nuclear staining, the
fraction of positively stained nuclei were estimated
(0 = 0%, 1 = < 1%, 2 = 1 – 10%, 3 = 11 – 33%, 4 = 34 –
66% and 5 = 67 – 100%). All samples with >10% stained
nuclei (score ≥ 3) were considered positive, and grouped
according to staining intensity (implying that a sample
with 50% stained nuclei and intensity score 2 would be
given 2 as a final score). Osteopontin and ephrin-A1
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and differentiating between weak and intermediate stain-
ing was difficult. Consequently, osteopontin and ephrin-
A1 immunoreactivity was scored according to a 0–2
scale, with 0 defined as negative (no staining), 1 as inter-
mediate staining and 2 as strong staining. The percent-
age of positive tumor cells was not evaluated for
S100A4c, ephrin-A1 and osteopontin because there was
uniform staining of the tumor cells in the vast majority
of cases, and thus the estimation of the fraction of
stained cells provided no additional information. For all
three biomarkers, the dominant staining intensity was
scored. Furthermore, at least two cores from different
tumor areas of the same specimen were included in the
TMA, and the staining intensity was highly similar in
the analysed cases.
Statistical analysis
Statistical analyses were performed using SPSS version
16.0 (SPSS Inc., Chicago, IL, USA). Associations between
expression of S100A4, ephrin-A1 and osteopontin, and
associations between immunohistochemical expression































Figure 1 Induction of ephrin-A1 expression by extracellular S100A4 in
NSCLC cell lines treated with 2 μg/ml and 10 μg/ml S100A4 for 6 hours (A
mean fold induction, n = 3, *p < 0.05. (C) Western blot of total cell lysates fr
indicated. Membranes were stained with anti-ephrin-A1, and α-tubulin wastwo-tailed Fisher´s exact test or linear by linear association
chi-square test. For the RT-PCR experiments, and to com-
pare the mean tumor size of the S100A4 negative and
positive tumors, two-tailed Student´s t-test was used. P
values < 0.05 were considered statistically significant.
Results
Induction of ephrin-A1 and osteopontin expression by
extracellular S100A4 in NSCLC cell lines
To investigate if S100A4 stimulates expression of
ephrin-A1 and osteopontin in NSCLC, two adenocarcin-
oma and two squamous cell carcinoma cell lines were
treated with 2 and 10 μg/ml recombinant S100A4 for 6
and 24 hours. Ephrin-A1 and osteopontin mRNA ex-
pression was analyzed by RT-PCR. As depicted in
Figure 1A and 1B extracellular S100A4 induced expres-
sion of ephrin-A1 in adenocarcinoma cell lines. In A549
cells, treatment with 2 μg/ml S100A4 increased the
ephrin-A1 mRNA levels 2.4 fold (p = 0.006) and 2.2 fold
(p = 0.03) after 6 h and 24 hours, respectively. The in-
duction was also confirmed at the protein level as shown
in Figure 1C. In EKVX cells, ephrin-A1 mRNA increased




























NSCLC cell lines. A and B) Fold induction of ephrin-A1 mRNA in
) and 24 hours (B) compared to untreated control cells. Bars represent
om A549 cells treated with 2 μg/ml S100A4 for 6 or 24 hours as
used as a loading control.




Gender Male 116 53
Female 101 47
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squamous cell carcinoma cell lines HTB-182 and SW900
did not show any significant regulation of ephrin-A1
upon S100A4 treatment. Furthermore, extracellular
S100A4 did not influence osteopontin levels in any of
the cell lines tested (data not shown).Age at surgery < 65 years 100 46
> 65 years 117 54
Histology Adenocarcinoma (incl. BAC) 132 61
Squamous cell carcinoma 60 28
Large cell carcinoma 25 11
Differentiation G1 (well differentiated) 18 9
G2 (moderately differentiated) 138 69
G3 (poorly differentiated) 45 22
Missing 16




Missing* 1Clinicopathological characteristics of the patient cohort
Next, we wanted to examine the expression of S100A4,
ephrin-A1 and osteopontin in NSCLC tumor tissue. At
the time of surgery, 217 patients with histologically veri-
fied NSCLC who underwent curatively intended surgical
resection were prospectively included. The clinical and
histopathological parameters of the study cohort are
summarized in Table 1. The cohort included 116 (53%)
males and 101 (47%) females, with a combined median
age of 66 years (range 39–83 years). The most common
histological type was adenocarcinoma (61%), followed by
squamous cell carcinoma (28%) and large cell carcinoma
(11%). The majority of the patients were in the early dis-
ease stages, with 63% in TNM stage I and 19% in TNM









pM 0 212 98
1 4 2
Missing* 1
Tumor size < 2.0 cm 58 27
2.1-3.0 cm 62 29
3.1-5.0 cm 65 30
5.1-7.0 cm 23 10
> 7.0 cm 8 4
Missing* 1
Surgery Lobectomy 147 68
Pulmectomy 26 12
Wedge resection 17 8
Bilobectomy 17 8
Other 10 4
Tobacco use Current smoker 74 34
Former smoker 129 60
Never smoker 14 6
* TNM stage missing in one patient due to exploratory surgery.Expression of S100A4, ephrin-A1 and osteopontin in
primary NSCLC
Of the 217 included patients, evaluable tumor tissue was
present in 196 cases. S100A4, ephrin-A1 and osteopon-
tin all displayed weak positive expression in normal al-
veolar and bronchial epithelial cells. In tumor stroma
most inflammatory cells were stained, and the positivity
was especially prominent in macrophages. However,
there was variation in staining intensity from weak to
strong for all three markers. The staining of normal cells
was not systematically assessed, and thus not further
analyzed. An overview of the immunohistochemical ex-
pression of S100A4, ephrin-A1 and osteopontin in
tumor cells is presented in Table 2, and representative
microscope images are shown in Figure 2. S100A4
immunoreactivity was apparent both in the cytoplasm
and in the nucleus. Twenty percent showed strong cyto-
plasmic staining, 37% were moderately positive, 41%
weakly positive and 2% negative. For nuclear staining
20% were strongly positive, 26% moderately positive,
34% weakly positive and 20% were negative. Ephrin-A1
was expressed both in the cytoplasm and on the cell
membrane, and 14% of the tumors were strongly posi-
tive and 72% moderately positive. Osteopontin immu-
noreactivity was detectable as granular cytoplasmic
staining in the tumor cells, and occasional staining of
tumor cell nuclei was also observed. In total, 77% of the
tumors were positive for osteopontin, with 12% of cases
showing strong staining and 65% displaying moderate
staining.
Table 2 Immunohistochemical expression of S100A4,
ephrin-A1 and osteopontin
Number Percent








Ephrin-A1 Negative 28 14
Moderate 142 72
Strong 26 14
Osteopontin Negative 45 23
Moderate 128 65
Strong 23 12
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with histology
Interestingly, the expression levels of S100A4c, S100A4n
and ephrin-A1 were significantly higher in adenocarcin-
omas compared to the squamous and large cell tumors
(Table 3). In fact, for both S100A4c and S100A4n 29% of
the adenocarcinomas showed strong staining, compared
to only 6% of the squamous cell carcinomas, and 4% of
the large cell tumors (p = 0.001). Eighteen percent of the
adenocarcinomas showed strong positive staining for
ephrin-A1, compared to 6% and 4% of the squamous
and large cell tumors, respectively (p = 0.004). The ex-
pression of osteopontin was evenly distributed in the dif-
ferent histological subtypes.Figure 2 Expression of S100A4, ephrin-A1 and osteopontin in primar
stained with anti-S100A4 (A and B), anti-ephrin-A1 (C and D) and anti-oste
whereas negative staining is shown in B, D and F.Association of S100A4, ephrin-A1 and osteopontin with
other clinicopathological parameters
A highly significant association between S100A4c and
tumor size was observed. Fifty-one percent of the
tumors with a diameter of more than 3.0 cm displayed
weak or negative cytoplasmic staining for S100A4, com-
pared to 36% for tumors less than 3.0 cm (Table 3). For
tumors with strong cytoplasmic S100A4 immunoreactiv-
ity, the mean tumor diameter was 2.6 cm, whereas the
mean diameter for S100A4c-negative or weakly stained
tumors was 3.4 cm (p = 0.02, independent samples t-
test). S100A4c staining did also vary relative to tumor
differentiation, as 24% of the well differentiated (grade 1)
tumors showed strong positive staining, compared to
only 7% of the poorly differentiated tumors (p = 0.05).
The associations between S100A4, ephrin-A1 and osteo-
pontin and other clinicopathological parameters are sum-
marized in Additional file 1. Furthermore, we performed
analyses including only the cases with adenocarcinoma
histology (n= 123, Additional file 2). Interestingly, we
found that S100A4c expression was related to pTNM
stage, with the highest levels of S100A4 found in stage I
patients (p= 0.04). In addition, an inverse association was
found between S100A4 staining and lymph node metasta-
sis (pN status) (p = 0.04). There was also an association be-
tween S100A4c expression and smoking habits in terms of
packyears (the number of packs of cigarettes smoked per
day multiplied by the number of years the person has
smoked); the patients who had smoked many packyears
tended to show strong positive S100A4c staining
(p= 0.02). In principal, the same associations were found
between nuclear S100A4 expression and the mentioned
clinicopathological parameters both in the whole patient
cohort, and when analyzing the adenocarcinoma group
separately. However, in the adenocarcinoma group we also
found that S100A4n staining was inversely associated withy NSCLC. Representative photomicrographs of NSCLC specimens
opontin (E and F). A, C and E demonstrate strong immunoreactivity,
Table 3 Associations between immunohistochemical expression, histology and tumor size
Histological subtype Tumor size
ADC (n =123) SCC (n = 49) LCC (n = 24) p value* ≤ 3.0 cm (n= 1 9) ≥ 3.1 cm (n = 87) p value*
S100A4c negative/weak 34% 57% 58% 36% 51%
moderate 37% 37% 38% 38% 36%
strong 29% 6% 4% 0.001 26% 13% 0.01
S100A4n negative 13% 33% 29% 18% 22%
weak 32% 34% 38% 29% 40%
moderate 26% 27% 29% 27% 25%
strong 29% 6% 4% 0.001 26% 13% 0.04
Ephrin-A1 negative 11% 29% 4% 15% 14%
moderate 71% 65% 92% 70% 75%
strong 18% 6% 4% 0.004 15% 11% 0.79
Osteopontin negative 23% 21% 25% 26% 20%
moderate 67% 61% 66% 62% 69%
strong 10% 18% 9% 0.61 12% 11% 0.54
* p value calculated by Fisher´s exact test or linear by linear association test as appropriate.
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tive for S100A4n, compared to 37% who had strong
S100A4n staining (p= 0.04, Additional file 2). No statisti-
cally significant associations were found between immu-
nohistochemical expression of S100A4, osteopontin or
ephrin-A1 and other clinicopathological parameters (Add-
itional file 1).
Associations between immunohistochemical expression
of S100A4, ephrin-A1 and osteopontin
In line with the in vitro data, S100A4 expression both in
the cytoplasm and nucleus was associated with ephrin-
A1 expression (Table 4; p = 0.02 and 0.06, respectively).
In more detail, we observed that 64% of S100A4c nega-
tive and weakly stained tumors were ephrin-A1-negative,
whereas only 27% were strongly positive for ephrin-A1.
Furthermore, among tumors that were negative for nu-
clear S100A4 staining, 40% were negative for ephrin-A1,
whereas 19% were ephrin-A1 strongly positive. There
was no association between S100A4 and osteopontin
expression. As expected, there was a highly significant
association between the expression of cytoplasmic and
nuclear S100A4 (p < 0.001) and among the S100A4cTable 4 Associations between the expression of S100A4,
ephrin-A1 and osteopontin
S100A4c S100A4n Ephrin-A1 Osteopontin
S100A4c < 0.001 0.02 0.72
S100A4n < 0.001 0.06 0.95
Ephrin-A1 0.02 0.06 0.06
Osteopontin 0.72 0.95 0.06
* p value calculated by linear by linear association test.negative cases, none displayed nuclear staining. When
selecting only the cases with adenocarcinoma histology
we found a significant association between ephrin-A1
and osteopontin expression (p = 0.005), but this associ-
ation was weaker (p = 0.06) when including all patients.
Discussion
In the present study we have demonstrated that extracel-
lular S100A4 stimulates the expression of ephrin-A1 in
NSCLC cell lines. Furthermore, we have characterized
the expression of S100A4, ephrin-A1 and osteopontin in
primary tumors from 217 NSCLC patients, and investi-
gated the associations between these biomarkers and
conventional clinicopathological parameters. Our group
has previously shown that extracellular S100A4 induces
the expression of ephrin-A1 and osteopontin in osteo-
sarcoma cell lines by activating the transcription factor
NF-κB [18,23]. Based on these results, we wanted to in-
vestigate whether S100A4-mediated induction of ephrin-
A1 and osteopontin also occurs in NSCLC cell lines.
Interestingly, we observed that S100A4 was able to in-
duce expression of ephrin-A1 both at the mRNA and
protein level in adenocarcinoma, but not in squamous
cell carcinoma cell lines. However, no S100A4-mediated
stimulation of osteopontin expression was found in any
of the cell lines tested. Importantly, a significant asso-
ciation was also found between expression of S100A4
and ephrin-A1 in primary tumor samples from NSCLC
patients, indicating that S100A4 stimulates ephrin-A1
expression both in vivo and in vitro.
We found high expression of ephrin-A1 in 13% and
intermediate expression in 72% of the tumors, and the
fact that ephrin-A1 is expressed in the majority of the
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biological role in NSCLC. However, ephrin-A1 was not
associated with any of the clinicopathological parameters
apart from histological type. Interestingly, we found that
adenocarcinomas had a higher percentage of S100A4
and ephrin-A1 positivity compared to squamous and
large cell tumors, and this finding is in keeping with that
of previous studies on S100A4 [7-9] and ephrin-A1 [25].
The histological subclasses of NSCLC differ not only in
their presentation in different regions of the lung and in
outcome [26], but also in molecular characteristics and
thereby in response to targeted therapies [27]. Con-
sequently, the differences in expression patterns of the
protein markers between the adenocarcinomas and
squamous cell carcinomas in this study are not surprising.
Expression of S100A4 in surgically resected NSCLC
specimens has previously been investigated in several
studies [7-11], and the percentage of S100A4 positive
cases in these studies range from 20-84%. In our study,
intermediate or strong cytoplasmic expression of S100A4
was observed in 57% of the cases, which is comparable to
the previous investigations. For osteopontin, high expres-
sion was found in 77% of the tumors, whereas in previ-
ous studies in NSCLC, osteopontin immunoreactivity
range from 38–67% [20,21,28-30]. In contrast to previous
reports, where an association between high expression
and squamous cell carcinoma has been described [28,30],
we did not find any significant associations between
osteopontin expression and conventional clinicopatho-
logical parameters.
Possible explanations for the contradicting results for
both S100A4 and osteopontin could be that different anti-
bodies, different immunohistochemical staining techni-
ques and different scoring systems were used. In the
present study we have used immunohistochemical stain-
ing of tissue microarrays. A potential disadvantage with
the use of TMA is the possibility that small tissue cores
do not adequately represent the tumor, especially in cases
with intratumoral heterogeneity. To evaluate whether the
expression patterns of the protein markers on the small
TMA cores were representative for the whole tumor, we
immunostained seven whole sections with the same anti-
bodies. The staining intensity of S100A4 and ephrin-A1
was generally homogenous across the sections, indicating
that the obtained results are indeed representative of the
whole tumor section. For osteopontin, however, some
intratumor heterogeneity was observed. Also of import-
ance, the majority of the mentioned studies have been
retrospectively conducted, and the patient cohorts may
therefore be biased. Our cohort was prospectively recruited,
and the distribution of gender and age at surgery corre-
sponds well with data from The Norwegian Association for
Cardiothoracic Surgery. Thus, we believe that this patient
population can be considered representative for patientswith early stage NSCLC undergoing primary surgery in
Norway.
S100A4 expression was associated with small tumor
size and high degree of differentiation, and when analyz-
ing the adenocarcinomas separately, significant inverse
associations between S100A4 expression and lymph
node metastasis as well as pTNM stage were found.
Given that S100A4 in general is associated with poor
prognosis and promotes metastasis in a number of
tumor types [4], this result was rather unexpected. Our
results are also in contrast to other investigations in
NSCLC where S100A4 expression was associated with
high TNM stage and poor outcome [9-11]. Importantly,
in our cohort of prospectively recruited patients S100A4
expression was associated with several parameters that
each reflects a less aggressive phenotype, suggesting that
the observed result could be of clinical relevance, but
further studies are required to clarify this issue.
How might we explain the unexpected result that
S100A4 is associated with a non-aggressive phenotype
in NSCLC? One of the most important biological func-
tions contributing to S100A4-induced metastasis is
increased cell migration and invasive capacity. However,
induction of S100A4 has also been shown to decrease
motility and invasiveness, such as in squamous cell car-
cinoma [31], and down-regulation of S100A4 in astro-
cytes increased their migratory capacity in vitro [32].
Furthermore, certain lines of evidence suggest that
S100A4 may have tumor suppressor functions in the
lung. S100A4 knockout mice, that were otherwise
phenotypically normal, were prone to spontaneous
tumor development, and the most frequent tumor
observed was carcinoma of the lung [33]. Taken to-
gether, these results indicate that the biological function
of S100A4 is cell type-dependent, and possibly, S100A4
may not play a pro-metastatic role in all tumor types.
One might also speculate that S100A4 could inhibit
tumor progression in the early stages of NSCLC devel-
opment, while promoting metastasis at later disease
stages, similar to the cytokine transforming growth fac-
tor β [34].
Moreover, our findings suggest that S100A4-induced
expression of ephrin-A1 may be one mechanism by
which S100A4 mediates its biological functions. If so,
one should assume that similar functions are attributed
to both proteins, and interestingly ephrin-A1 stimulates
both cellular motility [15], angiogenesis [13,14] and me-
tastasis [35], features that are also associated with
S100A4 [4]. However, seemingly contradictory results
have been reported for ephrin-A1, and overexpression of
ephrin-A1 or treatment with ephrin-A1-Fc (soluble re-
combinant ephrin-A1 fused to the Fc portion of IgG)
has been shown to inhibit invasiveness and reduce
tumor growth in bladder, pancreatic and gastric cancer,
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ephrin-A1-Fc was found to inhibit tumor growth and
migration in NSCLC cells [41]. Ephrin-A1 is supposed
to act as a tumor suppressor through its preferred recep-
tor EphA2 [25] which is overexpressed in NSCLC [41].
Similar to its ligand, the role of EphA2 in cancer is
somewhat conflicting. Increased expression is associated
with poor clinical outcome in several tumor types, in-
cluding NSCLC [3,25,42,43]. However, EphA2 can also
act as a tumor suppressor [43], and recently, high ex-
pression of both EphA2 and ephrin-A1 was found to be
related to favorable prognostic factors in stage I NSCLC
patients [25]. Based on our findings that S100A4 is
associated with small tumor size and a less aggressive
phenotype, one might speculate that S100A4-mediated
induction of ephrin-A1 could be implicated in reduced
tumor growth and invasiveness in NSCLC. However,
ephrin-A1 expression was not associated with tumor
size, differentiation or tumor stage, indicating that at
least these S100A4-associated features are independent
of ephrin-A1. Overall, these results suggest that ephrin-
A1 plays an important role in tumor progression, but the
exact function is complex, cell-type dependent and most
likely relies on many factors, including its preferred recep-
tor EphA2 [44]. Furthermore, the role of ephrin-A1 as a
biomarker still remains elusive, and especially in NSCLC
further studies are certainly required.
Conclusions
We have shown that in the present cohort of NSCLC
patients S100A4-positive tumors were smaller and more
differentiated than tumors without expression. It will be of
great interest to examine whether the observed associ-
ation between S100A4 expression and clinicopathological
parameters also influence on patient outcome, and this
will be investigated when follow-up data are available. Fur-
thermore, we have demonstrated that S100A4 induces ex-
pression of ephrin-A1 in lung adenocarcinoma cell lines,
and that the expression of these potential biomarkers is
significantly associated in the primary tumor samples. Fi-
nally, our findings contribute to an increased understand-
ing of the molecular characteristics of NSCLC, which
hopefully will foster improvements in diagnostics, thera-
peutic decisions and the development of novel therapies.
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